Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 8233

1.

Probing homodimer formation of epidermal growth factor receptor by selective crosslinking.

Sun X, Dusserre-Bresson F, Baker B, Zhang A, Xu P, Fibbe C, Noren CJ, Corrêa IR Jr, Xu MQ.

Eur J Med Chem. 2014 Jul 14. pii: S0223-5234(14)00648-5. doi: 10.1016/j.ejmech.2014.07.041. [Epub ahead of print]

PMID:
25042004
[PubMed - as supplied by publisher]
2.

Nomogram Predicting Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, Chung DH, Heo DS.

Cancer Res Treat. 2014 Jul 14. doi: 10.4143/crt.2013.120. [Epub ahead of print]

PMID:
25036571
[PubMed - as supplied by publisher]
Free Article
3.

Decoding the EGFR mutation-induced drug resistance in lung cancer treatment by local surface geometric properties.

Ma L, Wang DD, Huang Y, Wong MP, Lee VH, Yan H.

Comput Biol Med. 2014 Jun 28. pii: S0010-4825(14)00155-3. doi: 10.1016/j.compbiomed.2014.06.016. [Epub ahead of print]

PMID:
25035232
[PubMed - as supplied by publisher]
4.

M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma.

Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou W, Wang J, Yang B, Zhao Y, Rao Z, Gao J.

Med Oncol. 2014 Aug;31(8):127. doi: 10.1007/s12032-014-0127-0. Epub 2014 Jul 18.

PMID:
25034365
[PubMed - in process]
5.

[Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers].

Lyu X, Huang J, Liu J, Wang W, Su Y, Zhang W, Sun Y, Ying J, Wang J, Sun Y.

Zhonghua Zhong Liu Za Zhi. 2014 May;36(5):346-50. Chinese.

PMID:
25030589
[PubMed - in process]
6.

Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer.

Li N, Yang L, Ou W, Zhang L, Zhang SL, Wang SY.

PLoS One. 2014 Jul 16;9(7):e102777. doi: 10.1371/journal.pone.0102777. eCollection 2014.

PMID:
25029199
[PubMed - in process]
Free PMC Article
7.

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions.

Peters S, Zimmermann S, Adjei AA.

Cancer Treat Rev. 2014 Jul 1. pii: S0305-7372(14)00120-0. doi: 10.1016/j.ctrv.2014.06.010. [Epub ahead of print] Review.

PMID:
25027951
[PubMed - as supplied by publisher]
8.

Rapid Evaluation of Tyrosine Kinase Activity of Membrane-Integrated Human Epidermal Growth Factor Receptor Using the Yeast Gγ Recruitment System.

Fukuda N, Honda S.

ACS Synth Biol. 2014 Jul 9. [Epub ahead of print]

PMID:
25006755
[PubMed - as supplied by publisher]
9.

Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.

Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, Casey O, Chen WY, Fang L, Hynes P, Hsieh YY, Liu YN, Huang J, Kelly K.

Oncotarget. 2014 Jun 15;5(11):3770-84.

PMID:
25004126
[PubMed - in process]
Free Article
10.

Homogeneous time-resolved fluorescence-based assay to monitor extracellular signal-regulated kinase signaling in a high-throughput format.

Ayoub MA, Trebaux J, Vallaghe J, Charrier-Savournin F, Al-Hosaini K, Gonzalez Moya A, Pin JP, Pfleger KD, Trinquet E.

Front Endocrinol (Lausanne). 2014 Jun 23;5:94. doi: 10.3389/fendo.2014.00094. eCollection 2014.

PMID:
25002860
[PubMed]
Free PMC Article
11.

Efficacy and safety of gefitinib during pregnancy: Case report and literature review.

Gil S, Goetgheluck J, Paci A, Broutin S, Friard S, Couderc LJ, Ayoubi JM, Picone O, Tcherakian C.

Lung Cancer. 2014 Jun 16. pii: S0169-5002(14)00261-X. doi: 10.1016/j.lungcan.2014.06.003. [Epub ahead of print]

PMID:
24997732
[PubMed - as supplied by publisher]
12.

Challenges in the Management of EGFR -Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors.

Kuiper JL, Smit EF.

Oncology. 2014 Jul 3;87(2):83-94. [Epub ahead of print]

PMID:
24992911
[PubMed - as supplied by publisher]
13.

MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.

Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY.

Cancer Lett. 2014 Jun 28. pii: S0304-3835(14)00316-4. doi: 10.1016/j.canlet.2014.06.010. [Epub ahead of print]

PMID:
24983493
[PubMed - as supplied by publisher]
14.

Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Camidge DR, Pao W, Sequist LV.

Nat Rev Clin Oncol. 2014 Jul 1. doi: 10.1038/nrclinonc.2014.104. [Epub ahead of print]

PMID:
24981256
[PubMed - as supplied by publisher]
15.

A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker.

Wislez M, Malka D, Bennouna J, Mortier L, Bensadoun RJ, Sicard J, Dielenseger P, Rey JB, Moro-Sibilot D, Scotté F.

Bull Cancer. 2014 Jun 1;101(6):647-652.

PMID:
24977454
[PubMed - as supplied by publisher]
16.

Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge.

Zhang R, Tu L, Sun L.

J Thorac Dis. 2014 Jun;6(6):595-7. doi: 10.3978/j.issn.2072-1439.2014.04.36.

PMID:
24976979
[PubMed]
Free PMC Article
17.

Hypoxia-inducible Factor-1α Induces ErbB4 Signaling in the Differentiating Mammary Gland.

Paatero I, Seagroves TN, Vaparanta K, Han W, Jones FE, Johnson RS, Elenius K.

J Biol Chem. 2014 Jun 25. pii: jbc.M113.533497. [Epub ahead of print]

PMID:
24966332
[PubMed - as supplied by publisher]
Free Article
18.

Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.

Lai SW, Ho CL, Dai MS, Chen WL, Chang PY, Wu YY, Perng CL, Lai CY.

J BUON. 2014 Apr-Jun;19(2):459-65.

PMID:
24965407
[PubMed - in process]
19.

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.

Smyth EC, Sclafani F, Cunningham D.

Onco Targets Ther. 2014 Jun 12;7:1001-14. doi: 10.2147/OTT.S44941. eCollection 2014. Review.

PMID:
24959087
[PubMed]
Free PMC Article
20.

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?

Tartarone A, Lerose R, Lazzari C, Gregorc V, Aieta M.

Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5. Epub 2014 Jun 24.

PMID:
24958518
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk